For the quarter ending 2026-03-31, EMMA made $1,982K in revenue. -$4,253K in net income. Net profit margin of -214.58%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues, net | 1,982 | 3,852 | 3,378 | 2,817 |
| Cost of goods sold | 168 | 235 | 247 | 150 |
| Gross profit | 1,814 | 3,617 | 3,131 | 2,667 |
| Research and development | 40 | 31 | 50 | 56 |
| Selling | 747 | 898 | 655 | 674 |
| General and administrative | 1,850 | 1,802 | 1,731 | 2,307 |
| Total operating expenses | 2,637 | 2,731 | 2,436 | 3,037 |
| Loss from operations | -823 | 886 | 695 | -370 |
| Loss on debt extinguishment | -76 | -691 | -296 | -212 |
| Change in fair value of warrant derivative liabilities | -2 | -2 | 2 | 4 |
| Change in fair value of conversion feature derivative, notes payable | -235 | -324* | - | - |
| Realized gain on investment in convertible bond | - | 1,062* | - | -531 |
| Loss (gain) on lease modification | - | -738* | - | 861 |
| Foreign exchange gain (loss) | -130 | 76 | -32 | 134 |
| Interest and other income (net) | 61 | 65 | 65 | 67 |
| Interest expense | 2,126 | 2,269 | 1,931 | 1,678 |
| Total other expense | -2,508 | -2,821 | -2,192 | -1,355 |
| Loss before income taxes | -3,331 | -1,935 | -1,497 | -1,725 |
| Income tax provision | 4 | 16 | 579 | -590 |
| Net loss | -3,335 | -1,951 | -2,076 | -1,135 |
| Unrealized gain (loss) on debt securities available for sale (net of tax) | -940 | -2,259 | -1,734 | 3,715 |
| Reclassification adjustment for gain included in net gain | - | 0 | 0 | 354 |
| Foreign currency translation adjustment | 22 | 11 | 14 | -33 |
| Other comprehensive income (gain) | -918 | -2,248 | -1,720 | 4,036 |
| Comprehensive loss | -4,253 | -4,199 | -3,796 | 2,901 |
| Basic EPS | -0.05 | -0.065 | -0.03 | -0.02 |
| Diluted EPS | -0.05 | -0.065 | -0.03 | -0.02 |
| Basic Average Shares | 70,188,263 | 64,558,467 | 63,865,571 | 63,865,571 |
| Diluted Average Shares | 70,188,263 | 64,558,467 | 63,865,571 | 63,865,571 |
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)